The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Treatment of myeloma has benefited from the introduction of more effective and better tolerated agents, improvements in supportive care, better understanding of disease biology, revision of diagnostic criteria, and new sensitive and specific tools for disease prognostication and management. Assessment of minimal residual disease (MRD) in response to therapy is one of these tools, as longer progression-free survival (PFS) is seen consistently among patients who have achieved MRD negativity. Current therapies lead to unprecedented frequency and depth of response, and next-generation flow and sequencing methods to measure MRD in bone marrow are in use and being developed with sensitivities in the range of 10−5 to 10−6 cells. These technologies may be combined with functional imaging to detect MRD outside of bone marrow. Moreover, immune profiling methods are being developed to better understand the immune environment in myeloma and response to immunomodulatory agents while methods for molecular profiling of myeloma cells and circulating DNA in blood are also emerging. With the continued development and standardization of these methodologies, MRD has high potential for use in gaining new drug approvals in myeloma. The FDA has outlined two pathways by which MRD could be qualified as a surrogate endpoint for clinical studies directed at obtaining accelerated approval for new myeloma drugs. Most importantly, better understanding of MRD should also contribute to better treatment monitoring. Potentially, MRD status could be used as a prognostic factor for making treatment decisions and for informing timing of therapeutic interventions. Clin Cancer Res; 23(15); 3980–93. ©2017 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978 · cited 1×
“Progress has not been limited to the treatment arena, but has also included a better understanding of disease biology, revision of diagnostic criteria, as well as development of new sensitive and specific tools for disease prognostication (3-10).”
BackgroundSelf-citationKumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061 · cited 3×
“The new IMWG criteria are helpful in addressing this issue (20).”
BackgroundMethodInfluentialSelf-citationInternational uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632 · cited 1×
“Although this is applicable in the majority of patients, a small proportion of patients have no measurable monoclonal protein secretion, and direct assessment of the tumor burden is utilized (11).”
BackgroundSelf-citationAn ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C. W., Modlin, L. A., Liu, C. L., Neal, J. W., Wakelee, H. A., Merritt, R. E., et al. (2014) · Nature Medicine · doi:10.1038/nm.3519 · Cited by 2,220 · cited 1×
“To detect MRD will require integration of molecular barcoding techniques to enable error suppression at levels <10 (49, 50) as well as expansion of the targeted genomic regions to increase detection of low-frequency mutant alleles (51), including new markers of resistant clones.”
BackgroundCarfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411321 · Cited by 1,332 · cited 1×
“the recent ASPIRE trial (85), making future trials targeting PFS long, complicated, and costly.”
BackgroundWidespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
Lohr, J. G., Stojanov, P., Carter, S. L., Cruz-Gordillo, P., Lawrence, M. S., Auclair, D., Sougnez, C., Knoechel, B., Gould, J., Saksena, G., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2013.12.015 · Cited by 988
Self-citationLenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Benboubker, L., Dimopoulos, M. A., Dispenzieri, A., Catalano, J., Belch, A. R., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402551 · Cited by 793 · cited 1×
“In the FIRST trial (83) comparing 18 months of lenalidomide to lenalidomide until progression, PFS was superior for the indefinite lenalidomide, with no improvement in OS.”
MethodSelf-citationDetecting ultralow-frequency mutations by Duplex Sequencing
Kennedy, S. R., Schmitt, M. W., Fox, E. J., Kohrn, B. F., Salk, J. J., Ahn, E. H., Prindle, M. J., Kuong, K. J., Shen, J.-C., Risques, R.-A., et al. (2014) · Nature Protocols · doi:10.1038/nprot.2014.170 · Cited by 503 · cited 1×
“To detect MRD will require integration of molecular barcoding techniques to enable error suppression at levels <10 (49, 50) as well as expansion of the targeted genomic regions”
BackgroundPalumbo, A., Gay, F., Cavallo, F., Di Raimondo, F., Larocca, A., Hardan, I., Nagler, A., Petrucci, M. T., Hajek, R., Pezzatti, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.2466 · Cited by 150
Self-citation
Cited by
van de Donk, N. W. C. J., Pawlyn, C., & Yong, K. L. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00135-5 · Cited by 869
Munshi, N. C., Avet-Loiseau, H., Anderson, K. C., Neri, P., Paiva, B., Samur, M., Dimopoulos, M., Kulakova, M., Lam, A., Hashim, M., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002827 · Cited by 431
“Discussion Recent studies have demonstrated the utility of MRD as a prognostic biomarker for PFS and OS outcomes, wherein achievement of MRD-negative status was associated with a significant improvement in both PFS and OS.(6,9,23,60,61) However, these studies were relatively small and included primarily transplant-eli…”
ResultSelf-citationThe multiple myelomas — current concepts in cytogenetic classification and therapy
Kumar, S. K., & Rajkumar, S. V. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0018-y · Cited by 302
Self-citationRosiñol, L., Oriol, A., Rios, R., Sureda, A., Blanchard, M. J., Hernández, M. T., Martínez-Martínez, R., Moraleda, J. M., Jarque, I., Bargay, J., et al. (2019) · Blood · doi:10.1182/blood.2019000241 · Cited by 219
Metadata
- Authors
- Anderson, K. C., Auclair, D., Kelloff, G. J., Sigman, C. C., Avet-Loiseau, H., Farrell, A. T., Gormley, N. J., Kumar, S. K., Landgren, O., Munshi, N. C., Cavo, M., Davies, F. E., Di Bacco, A., Dickey, J. S., Gutman, S. I., Higley, H. R., Hussein, M. A., Jessup, J. M., Kirsch, I. R., Little, R. F., Loberg, R. D., Lohr, J. G., Mukundan, L., Omel, J. L., Pugh, T. J., Reaman, G. H., Robbins, M. D., Sasser, A. K., Valente, N., & Zamagni, E.
- Venue
- Clinical Cancer Research
- Published
- 2017-08-01
- Volume
- 23
- Issue
- 15
- Pages
- 3980-3993
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2606664616
- Cited by
- 91
- References
- 9
- FWCI
- 7.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-16-2895
- The paper
- Anderson, K. C., Auclair, D., Kelloff, G. J., Sigman, C. C., Avet-Loiseau, H., Farrell, A. T., Gormley, N. J., Kumar, S. K., Landgren, O., Munshi, N. C., Cavo, M., Davies, F. E., Di Bacco, A., Dickey, J. S., Gutman, S. I., Higley, H. R., Hussein, M. A., Jessup, J. M., Kirsch, I. R., . . . Zamagni, E. (2017). The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-16-2895
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.